Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS

Trial Profile

Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms REFALS
  • Sponsors Orion; Orion Pharma
  • Most Recent Events

    • 09 Dec 2019 According to an Orion media release, data from this trial was presented at the 30th International Symposium on ALS/MND in Perth, Australia last week
    • 02 Dec 2019 According to an Orion media release, baseline characteristics and status update on the progression of this trial will be presented at the 30th International Symposium on ALS/MND held on 4-6 December 2019 in Perth, Australia.
    • 23 Oct 2019 According to an Orion media release, this trial is expected to complete in the summer of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top